Linked Life Data

20808813

Source:http://linkedlifedata.com/resource/pubmed/id/20808813

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-9-2
pubmed:abstractText
Although a variety of genetic strategies have been developed to inhibit HIV replication, few direct comparisons of the efficacy of these inhibitors have been carried out. Moreover, most studies have not examined whether genetic inhibitors are able to induce a survival advantage that results in an expansion of genetically-modified cells following HIV infection. We evaluated the efficacy of three leading genetic strategies to inhibit HIV replication: 1) an HIV-1 tat/rev-specific small hairpin (sh) RNA; 2) an RNA antisense gene specific for the HIV-1 envelope; and 3) a viral entry inhibitor, maC46. In stably transduced cell lines selected such that >95% of cells expressed the genetic inhibitor, the RNA antisense envelope and viral entry inhibitor maC46 provided the strongest inhibition of HIV-1 replication. However, when mixed populations of transduced and untransduced cells were challenged with HIV-1, the maC46 fusion inhibitor resulted in highly efficient positive selection of transduced cells, an effect that was evident even in mixed populations containing as few as 1% maC46-expressing cells. The selective advantage of the maC46 fusion inhibitor was also observed in HIV-1-infected cultures of primary T lymphocytes as well as in HIV-1-infected humanized mice. These results demonstrate robust inhibition of HIV replication with the fusion inhibitor maC46 and the antisense Env inhibitor, and importantly, a survival advantage of cells expressing the maC46 fusion inhibitor both in vitro and in vivo. Evaluation of the ability of genetic inhibitors of HIV-1 replication to confer a survival advantage on genetically-modified cells provides unique information not provided by standard techniques that may be important in the in vivo efficacy of these genes.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1932-6203
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e12357
pubmed:dateRevised
2011-5-13
pubmed:meshHeading
pubmed-meshheading:20808813-Animals, pubmed-meshheading:20808813-CD4-Positive T-Lymphocytes, pubmed-meshheading:20808813-Cell Line, pubmed-meshheading:20808813-Cell Membrane, pubmed-meshheading:20808813-Cell Survival, pubmed-meshheading:20808813-Gene Expression, pubmed-meshheading:20808813-Gene Therapy, pubmed-meshheading:20808813-HIV Fusion Inhibitors, pubmed-meshheading:20808813-HIV Infections, pubmed-meshheading:20808813-HIV-1, pubmed-meshheading:20808813-Humans, pubmed-meshheading:20808813-Mice, pubmed-meshheading:20808813-RNA, Antisense, pubmed-meshheading:20808813-Recombinant Fusion Proteins, pubmed-meshheading:20808813-Species Specificity, pubmed-meshheading:20808813-Transduction, Genetic, pubmed-meshheading:20808813-Virus Internalization, pubmed-meshheading:20808813-Virus Replication
pubmed:year
2010
pubmed:articleTitle
Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection.
pubmed:affiliation
Angewandte Virologie und Gentherapie, Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt, Germany.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural